Literature DB >> 12471623

Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system.

Ekaterina S Jordanova1, Sietske A Riemersma, Katja Philippo, Ed Schuuring, Philip M Kluin.   

Abstract

Human leukocyte antigen (HLA) class I molecules are expressed on the surface of all nucleated cells and present antigenic peptides to cytotoxic T cells, thereby playing an important role in initiating the cellular anti-tumor immune response. We previously reported that loss of HLA class I expression in diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) and the testis is a common event. Loss of expression and mutations of the light chain of the HLA class I molecule, beta(2)-microglobulin (beta(2)m) have been described in a variety of human tumors and cell lines. In our study, we screened 15 DLBCL cases with a combined loss of HLA class I and beta(2)m expression for mutations in the latter gene by direct sequencing. Frame shift mutations in repetitive sequences within the beta(2)m gene leading to loss of functional beta(2)m were detected in 2 cases. Loss of heterozygosity (LOH) and fluorescent in situ hybridization (FISH) analysis for chromosome 15 exhibited loss of the remaining copy of the beta(2)m gene in both cases but also hemizygous deletions and monosomies in 6 additional cases. Since similar mutations in the beta(2)m gene have been associated with microsatellite instability (MSI), we used 8 markers to study MSI involvement in DLBCL. Low MSI was more frequent (33%) as compared to nodal DLBCL (n=15) but did not correlate with the beta(2)m mutations. Our data indicate that multiple mechanisms lead to downregulation of beta(2)m and concomitant loss of HLA class I expression in DLBCL. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12471623     DOI: 10.1002/ijc.10824

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Authors:  Madhavi Challa-Malladi; Yen K Lieu; Olivia Califano; Antony B Holmes; Govind Bhagat; Vundavalli V Murty; David Dominguez-Sola; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

2.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.

Authors:  Stefano Monti; Bjoern Chapuy; Kunihiko Takeyama; Scott J Rodig; Yansheng Hao; Kelly T Yeda; Haig Inguilizian; Craig Mermel; Treeve Currie; Ahmet Dogan; Jeffery L Kutok; Rameen Beroukhim; Donna Neuberg; Thomas M Habermann; Gad Getz; Andrew L Kung; Todd R Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

3.  Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.

Authors:  L Deng; Z Y Xu-Monette; S Loghavi; G C Manyam; Y Xia; C Visco; J Huh; L Zhang; Q Zhai; Y Wang; L Qiu; K Dybkær; A Chiu; A M Perry; S Zhang; A Tzankov; H Rao; J Abramson; A R Sohani; M Xu; E D Hsi; J Zhu; M Ponzoni; S Wang; Ling Li; M Zhang; A J M Ferreri; B M Parsons; Y Li; M A Piris; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

Review 4.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

5.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

6.  HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.

Authors:  Jan Willem F Dierssen; Noel F C C de Miranda; Soldano Ferrone; Marjo van Puijenbroek; Cees J Cornelisse; Gert Jan Fleuren; Tom van Wezel; Hans Morreau
Journal:  BMC Cancer       Date:  2007-02-22       Impact factor: 4.430

7.  Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.

Authors:  Rui Wu; Marcel Nijland; Bea Rutgers; Rianne Veenstra; Myra Langendonk; Lotte E van der Meeren; Philip M Kluin; Guanwu Li; Arjan Diepstra; Jen-Fu Chiu; Anke van den Berg; Lydia Visser
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 8.  Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

9.  A Missing Link between Neuron Specific Enolase Release and Poor Prognosis in Aging Patients with B-cell Lymphoma.

Authors:  Rachel Polcyn; Jason God; Mollie Capone; Denise Matzelle; Naren L Banik; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2018-05-15

10.  Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Authors:  Claire Galand; Sabrina Donnou; Thierry Jo Molina; Wolf Herman Fridman; Sylvain Fisson; Catherine Sautès-Fridman
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.